How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,238 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis (PubMed)

Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis Clostridium difficile infection (CDI) is the most common cause of health-care-associated infectious diarrhea. Recurrence rates are as high as 20-30% after standard treatment with metronidazole or vancomycin, and appear to be reduced for patients treated with fidaxomicin. According to the literature, the risk of CDI recurrence increases after the second relapse to 30-65%. Accurate data (...) for Germany are not yet available.Based on the research database of arvato health analytics (Munich, Germany), a secondary data analysis for the incidence, treatment characteristics and course of CDI was performed. The database included high granular accounting information of about 1.46 million medically insured patients covering the period 2006-2013, being representative for Germany. The analysis was based on new-onset CDI in 2012 in patients which either received outpatient antibiotic therapy for CDI

Full Text available with Trip Pro

2016 Infectious diseases and therapy

62. Syphilis: an atypical case of sepsis and multiple anogenital lesions in secondary syphilis (PubMed)

with severe septic shock and multiple anogenital lesions in an immunocompetent host. A 22-year-old male with no significant past medical history presented with fevers, chills, sore throat, diaphoresis, and diarrhea. He was febrile, tachycardic, hypotensive, and unresponsive to fluid resuscitation requiring short-term vasopressor support. Physical exam revealed diffuse lymphadenopathy; lower extremity macular rash involving the soles of the feet; papular non-pustular lesions on the scrotum; and a 0.5 cm (...) Syphilis: an atypical case of sepsis and multiple anogenital lesions in secondary syphilis The incidence of syphilis has historically been cyclical in nature, often in relation to the rise and fall of public health initiatives directed toward eradication along with social attitudes toward sexual practices. The incidence of syphilis has increased by 15% in the last 6 years in the United States, with similar increases worldwide. Herein, we present an atypical case of syphilis presenting

Full Text available with Trip Pro

2016 Journal of community hospital internal medicine perspectives

63. Pharmacoepidemiological Study of Secondary Hyperparathyroidism in Lorraine

/DOQI Secondary Outcome Measures : Phosphocalcium product level [ Time Frame: 2 years ] Serum calcium level [ Time Frame: 2 years ] Serum phosphorus level [ Time Frame: 2 years ] Symptoms and / or clinical events caused by hyperparathyroidism [ Time Frame: 2 years ] using clinical and paraclinical examinations Tolerance of therapeutic interventions: nausea, vomiting, diarrhea, hypocalcemia [ Time Frame: 2 years ] using clinical and paraclinical examinations The quality of life [ Time Frame: 2 years (...) but dialysed in a unit outside Lorraine. Diagnosis of secondary hyperparathyroidism with higher parathormone or equal to 500 pg / ml placed before 1/4/2009. Patient who have received medical treatment with cinacalcet or by surgical parathyroidectomy for secondary hyperparathyroidism. Patient expressing opposition to the collection of information. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research

2016 Clinical Trials

64. Causes of variability in prevalence rates of communicable diseases among secondary school Students in Kisumu County, Kenya (PubMed)

in female (7.96%) than male students.This study has revealed that the prevalences of diarrhea, tuberculosis, pneumonia and other respiratory tract infections are lower among female secondary school students than males and that the prevalence of malaria is higher in males than females. Age of secondary school students is a significant vulnerability factor for malaria, diarrhea, tuberculosis and pneumonia, which were the important communicable diseases most prevalent among secondary school students (...) Causes of variability in prevalence rates of communicable diseases among secondary school Students in Kisumu County, Kenya To determine causes of variability in communicable disease prevalence rates among students in secondary schools to inform policy formulation in the public health sector.A representative cluster sample size for students was estimated using Fisher et al.'s formula while schools, sub-counties and education zones were clustered and sample size was calculated based

Full Text available with Trip Pro

2016 Zeitschrift Fur Gesundheitswissenschaften

65. Medical Management of Kidney Stones

. Hypocitraturia is a common risk factor for stone disease with an estimated prevalence of 20-60%. 81, 82 Urinary citrate excretion is determined by acid-base status; metabolic acidosis or dietary acid loads enhance renal citrate reabsorption, thereby reducing urinary excretion. A number of medical conditions such as renal tubular acidosis and chronic diarrhea, and some medications, such as carbonic anhydrase inhibitors, may promote hypocitraturia. 82 Acidosis can arise from a diet that is inordinately rich (...) Medical Management of Kidney Stones Kidney Stones: Medical Mangement Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students Exams

2014 American Urological Association

66. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics

Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics 1 © American College of Medical Genetics and Genomics ACMG St And ArdS And GuidelineS PURPOSE This guideline is intended as an educational resource. It high- lights current practices and therapeutic approaches to the diagnosis and management of GSD I and its early and long- term complications. GENERAL BACKGROUND History In 1929, von Gierke described glycogen (...) storage disease type I (GSD I) after reviewing the autopsy reports of two children whose livers and kidneys contained excessive amounts of Submitted 12 August 2014; accepted 12 August 2014; advance online publication 6 November 2014. doi:10.1038/gim.2014.128 Genet Med 00 00 2014 Genetics in Medicine 10.1038/gim.2014.128 ACMG Standards and Guidelines 00 00 12August2014 12August2014 © American College of Medical Genetics and Genomics 6November2014 Purpose: Glycogen storage disease type I (GSD I

2014 American College of Medical Genetics and Genomics

67. Inulin-Type Fructan Supplementation of 3 to 6 Year-Old Children Is Associated with Higher Fecal Bifidobacterium Concentrations and Fewer Febrile Episodes Requiring Medical Attention. (PubMed)

Inulin-Type Fructan Supplementation of 3 to 6 Year-Old Children Is Associated with Higher Fecal Bifidobacterium Concentrations and Fewer Febrile Episodes Requiring Medical Attention. Inulin-type fructans used in formula have been shown to promote microbiota composition and stool consistency closer to those of breastfed infants and to have beneficial effects on fever occurrence, diarrhea, and incidence of infections requiring antibiotic treatment in infants.The primary study aim was to explore (...) whether prophylactic supplementation with prebiotic fructans is able to influence the frequency of infectious diseases in kindergarten children during a winter period. A secondary objective was to ascertain the effect on the intestinal microbiota.142 boys and 128 girls aged 3-6 y were randomly allocated to consume 6 g/d fructans or maltodextrin for 24 wk. At baseline, stool samples were collected for microbiota analysis and anthropometric measurements were made. During the intervention period

Full Text available with Trip Pro

2018 Journal of Nutrition

68. Medical Treatment for Microscopic Colitis: A Community Hospital’s Experience (PubMed)

Medical Treatment for Microscopic Colitis: A Community Hospital’s Experience Lymphocytic colitis (LC) is a chronic disorder characterized by watery diarrhea. This study sought to evaluate if LC recurs after therapy, and the time frame in which this occurs. Secondary objectives included length and type of therapy, drug-free intervals, and reasons for drug discontinuation.A retrospective chart review between January 1, 2008 and October 30, 2015 of patients with biopsy-confirmed lymphocytic (...) , collagenous, or microscopic colitis was conducted. Patient-reported average bowel movements/day were reviewed. Demographic data, dates of colonoscopy, follow-up, type and dose of medications used, and therapy start/stop dates were reviewed.Patients presenting with colonoscopic documented LC (n = 114) were predominantly female (88%), Caucasian (97%), with mean bowel movements/day of five. A total of 58/114 (51%) patients were placed on a therapy. Patients taking budesonide saw bowel movements/day reduced

Full Text available with Trip Pro

2018 Gastroenterology research

69. Branched Chain Amino Acids Ratio in Medical Foods

Branched Chain Amino Acids Ratio in Medical Foods Branched Chain Amino Acids Ratio in Medical Foods - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Branched Chain Amino Acids Ratio in Medical Foods (...) by (Responsible Party): Rajavel Elango, PhD, University of British Columbia Study Details Study Description Go to Brief Summary: This study will evaluate the branched-chain amino acids (BCAA) ratio in the medical foods formulated for Methylmalonic and Propionic Acidemias (MMA/PROP) patients. We will recruit 6 healthy children between 6-10y (3 boys and 3 girls). They will be given amino acid-based shakes and protein free cookies. Using a minimally invasive stable isotope based technique, we will be able

2018 Clinical Trials

70. Bladder Antimuscarinic Medication and Accidental Bowel Leakage

: Severe constipation, fecal impaction or overflow fecal incontinence Inflammatory bowel disease, colorectal CA, spinal cord injury, multiple sclerosis, stroke, myasthenia gravis Infectious diarrhea Bothersome SUI (defined as "moderately" or greater bother on UDI-3) Patients planning to undergo surgery during study period Patients who are pregnant or intending to become pregnant during the study period Patients with contraindications to antimuscarinic medications (ie. closed angle glaucoma) Patients (...) Bladder Antimuscarinic Medication and Accidental Bowel Leakage Bladder Antimuscarinic Medication and Accidental Bowel Leakage - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Bladder Antimuscarinic

2018 Clinical Trials

71. Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome

Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02565654 Recruitment Status : Unknown Verified June 2015 by XiaojunZhuang, First Affiliated Hospital, Sun Yat-Sen University. Recruitment status was: Not yet recruiting First

2015 Clinical Trials

72. Probiotics in the Reduction of Antibiotic Associated Diarrhea

. Outcome Measures Go to Primary Outcome Measures : Antibiotic Associated Diarrhea [ Time Frame: 21 days after starting study treatment ] Subjects will be asked to keep a diary for 20 days after starting study treatment and will be contacted by a nurse approximately 21 days after starting study treatment Secondary Outcome Measures : Length of stay [ Time Frame: during hospitalization up to 4 weeks ] Mortality [ Time Frame: During hospitalization up to 4 weeks ] Healthcare costs [ Time Frame: During (...) coherency to understand consent Active Diarrhea at admission Non-controlled intestinal disease Documented positive C. difficile infection within the 3 months before enrollment Antibiotic use at hospital admission Immunosuppressive therapy Pregnancy Allergic to ingredients in Florajen-3 Allergic to ingredients in placebo Immunocompromised state including: HIV with a low CD4 count Active malignancy receiving chemotherapy Medications including long-term steroids (>2 weeks), and disease modifying biologic

2015 Clinical Trials

73. Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT

burden and nausea were barriers) First Posted : December 2, 2015 Results First Posted : June 14, 2017 Last Update Posted : June 14, 2017 Sponsor: Mayo Clinic Collaborator: Entera Health, Inc Information provided by (Responsible Party): Michael Camilleri, Mayo Clinic Study Details Study Description Go to Brief Summary: For patients who receive a hematopoietic cell transplant (HCT), there is a risk of developing a diarrhea secondary to the chemotherapy which we give. Diarrhea is usually harmless (...) the Bristol Stool Scale. The Bristol Stool Scale is a medical aid designed to classify the form of human feces into seven categories or types. Types 1 and 2 indicate constipation with 3 and 4 being the "ideal stools" especially the latter, as they are the easiest to defecate, and 5-7 tending towards diarrhea. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends

2015 Clinical Trials

74. Comparative Evaluation of Herbal and Allopathic Drugs for the Treatment of Chronic Diarrhea

[ Time Frame: 5 days ] The primary efficacy criterion will be the frequency and consistency of diarrhea in hours, from the first treatment dose to recovery. It will be evaluated through stool D/R. Stool D/R described the consistency, frequency and other important features of stool. Semisolid stool consistency with 1-2/day will be considered significant. Secondary Outcome Measures : Improvement in clinical symptoms such as abdominal pain, abdominal distension, etc will be secondary outcome measures (...) Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Male or female adults between the age of 18-60 years who were suffering from diarrhea of presumed infectious origin and willing to participate were eligible for inclusion in the study. Exclusion Criteria: Exclusion criteria were the presence of chronic Iatrogenic, or bloody diarrhea, having received antibiotic treatment for other medical or surgical problems Having a history of renal or hepatic dysfunction Having

2015 Clinical Trials

75. Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir

days). ] The overall incidence of diarrhea, represented as a percentage of patients, that develop diarrhea during the course of their enrollment in the study (an average of 35 days). Secondary Outcome Measures : Incidence of Clostridium difficile infection among the three randomized study groups over time [ Time Frame: Assessed at any point during a patient's enrollment in the study (average of 35 days) when clinical symptoms require a C. difficile test per standard of care. Individual patients (...) Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2015 Clinical Trials

76. Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome

Information provided by (Responsible Party): Chengdu University of Traditional Chinese Medicine Study Details Study Description Go to Brief Summary: The purpose of this study is to test the efficacy and safety of a traditional Chinese medication Tong-Xie-Yao-Fang for patients with diarrhea-predominant irritable bowel Syndrome (IBS-D). Condition or disease Intervention/treatment Phase Diarrhea-predominant Irritable Bowel Syndrome Drug: Tong-Xie-Yao-Fang Drug: Placebo Phase 2 Phase 3 Detailed Description (...) Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Tong

2015 Clinical Trials

77. Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children

]) and no other copathogen. Secondary Outcome Measures : Time to first event of diarrhea due to ST-only ETEC expressing a vaccine-shared CF (ST-VCF-ETEC) as defined below, and no other copathogen.. [ Time Frame: 365-day period starting 14 days after the third vaccination ] Time to first event of diarrhea associated with excretion of ST-VCF-ETEC (defined as ETEC expressing ST-only plus any vaccine-shared colonization factor [i.e., CFA/I, CS1, CS2, CS3, CS4, and/or CS5]) and no other copathogen. All events (...) table for investigator information Principal Investigator: Stephen Savarino, MD, MPH Naval Medical Research Center More Information Go to Layout table for additonal information Responsible Party: U.S. Army Medical Research and Materiel Command ClinicalTrials.gov Identifier: Other Study ID Numbers: HSRRB A-7965 First Posted: September 22, 2015 Last Update Posted: October 12, 2015 Last Verified: October 2015 Additional relevant MeSH terms: Layout table for MeSH terms Diarrhea Signs and Symptoms

2015 Clinical Trials

78. Effects of Bifidobacterium Longum BB536 on Incidence of Acute Diarrhea and/or Respiratory- Related Illnesses in Children

Outcome Measures : Absentia between BB536 vs. Placebo children in daycare centers due to diarrhea and/or respiratory-related illnesses [ Time Frame: 10 monhts ] Severity of diarrhea between BB536 vs. Placebo children [ Time Frame: 10 months ] Severity of respiratory-related illnesses between BB536 vs. Placebo children [ Time Frame: 10 months ] Secondary Outcome Measures : Fecal microbiota profiles of BB536 vs. Placebo children [ Time Frame: 10 months ] Eligibility Criteria Go to Information from (...) Effects of Bifidobacterium Longum BB536 on Incidence of Acute Diarrhea and/or Respiratory- Related Illnesses in Children Effects of Bifidobacterium Longum BB536 on Incidence of Acute Diarrhea and/or Respiratory- Related Illnesses in Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2015 Clinical Trials

79. Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea

: Uniformed Services University of the Health Sciences Collaborators: Naval Medical Research Center Ministry of Defence, United Kingdom Information provided by (Responsible Party): Ramiro Gutierrez, Naval Medical Research Center Study Details Study Description Go to Brief Summary: The purpose of this study is to develop evidence on the relative efficacy of 2 rifaximin chemoprophylaxis regimens for the prevention of Travelers' Diarrhea (TD) in a deployed setting. An additional purpose is to explore (...) aid [ Time Frame: 24hr ] Secondary Outcome Measures : Efficacy as determined by use of a symptom memory aid. [ Time Frame: For a duration of prophylaxis which will be on average 3-4 weeks or a maximum of 6 weeks ] Proportion of subjects in each treatment group with TD, with mild diarrhea, with TD associated with isolation of a pathogen and pathogen type, total diarrhea days, work days and performance loss due to diarrhea, comparison of incidence of TD Solicited adverse events as collected from

2015 Clinical Trials

80. Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence

. For participants who withdraw from the trial due to reasons other than complete resolution of the symptoms of diarrhea, TTLUS is defined as the number of hours from the start of the trial to the time of withdrawal. Time to Complete Amelioration of Abdominal Discomfort [ Time Frame: 48 hours ] The time over which abdominal discomfort caused by gastrointestinal gas accumulation is completely resolved. Secondary Outcome Measures : Number of Participants With Complete Remission of Diarrhea [ Time Frame: Up to 48 (...) Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>